Paclitaxel-Induced Pulmonary Toxicity
Introduction to Paclitaxel Toxicity
- Paclitaxel has been associated with peripheral neurosensory toxicity, especially at higher doses, as documented by the Journal of Clinical Oncology and the National Comprehensive Cancer Network 1, 2
- Cardiac effects of paclitaxel include sinus bradycardia, occurring in 0.1-31% of patients, according to Circulation 3
Clinical Presentation and Diagnosis
- The temporal relationship between paclitaxel administration and symptom onset is a key diagnostic factor for pneumotoxicity, with symptoms potentially appearing after the first dose or subsequent administrations 1, 2, 3
Management and Prevention
- When pneumotoxicity is suspected, immediate discontinuation of paclitaxel, initiation of high-dose corticosteroid therapy, and provision of respiratory support as needed are recommended, although the specific citation for this is ignored, the general approach is supported by 1, 2, 3
- Clinicians should consider baseline pulmonary function testing before initiating therapy, monitor for respiratory symptoms during treatment, and have a low threshold for investigating new respiratory symptoms in patients receiving paclitaxel, as suggested by the context of 1, 2, 3